The U.S. Food and Drug Administration granted official regulatory approval to Tonix Pharmaceuticals for its proprietary flagship drug candidate, Tonmya (cyclobenzaprine hydrochloride sublingual tablets), for the management of fibromyalgia in adults. While the corporate ticker symbol TNXP represents the publicly traded equity of the company itself rather than a specific drug product, the regulatory approval of its lead pharmaceutical asset marked a major validation milestone for the organization's proprietary sublingual formulation technology and clinical development strategy.